Page 1

AstraZeneca PLC 29 July 2021 07:00 BST H1 2021 results Accelerating top - line growth with continued pipeline progress underpins the transition to long - term sustainable growth AstraZeneca delivered strong revenue growth of 23 % ( 18 % at CER¹ ) in the half to $ 15,540m while , in the second quarter , revenue increased by 31 % ( 25 % at CER ) to $ 8,220m . Excluding the contribution from the pandemic COVID - 19 vaccine , revenue increased by 14 % ( 9 % at CER ) in the half to $ 14,371m and by 17 % ( 12 % at CER ) in the quarter to $ 7,326m . Further pipeline progress and the recent acquisition of Alexion Pharmaceuticals Inc. ( Alexion ) supports the Company's transition to long - term sustainable growth . AstraZeneca is updating its full - year 2021 guidance to reflect the contribution of Alexion in the year . Pascal Soriot , Chief Executive Officer , commented : " AstraZeneca has delivered another period of strong growth thanks to robust performances across all regions and disease areas , particularly Oncology , New CVRM and Fasenra in Respiratory . As a result , we have delivered further earnings progression , supported ongoing launches , and continued our investment in R & D . We continue to advance our portfolio of life - changing medicines with further significant progress across disease areas . In Oncology , we recently presented Lynparza's OlympiA Phase III trial at the plenary session the 2021 American Society of Clinical Oncology Annual Meeting , and we also shared the final results from Calquence's head - to - head trial with ibrutinib . In BioPharmaceuticals , the US approved Farxiga for chronic kidney disease and granted tezepelumab Priority Review to treat patients with asthma . Alexion will enable us to enhance our pipeline , extending the Company's presence in rare diseases and immunology with its complement biology . Following the successful acquisition of Alexion , we are today updating our full - year 2021 guidance ; our long term goals to accelerate scientific discovery , invest for sustainable growth and deliver more benefits for patients remains unchanged . " Table 1 : Financial summary $ m 15,302 238 Actual % Change 24 ( 12 ) 23 n / m³ 14 37 26 n / m 15,540 1,169 14,371 $ 1.61 $ 2.53 $ ( 0.04 ) AstraZeneca What science can do H1 2021 CER % change 19 ( 12 ) 18 n / m $ m 8,045 175 9 45 27 n / m Product Sales Collaboration Revenue Total Revenue - Less pandemic COVID - 19 vaccine² Total Revenue ex - pandemic vaccine + Reported 5 EPS6 Core EPS Impact of pandemic vaccine on EPS Highlights of Total Revenue in the half included : An increase in Product Sales of 24 % ( 19 % at CER ) to $ 15,302m . New medicines8 Total Revenue improved by 31 % ( 27 % at CER ) in the half to $ 8,332m , including growth in Emerging Markets of 35 % ( 29 % at CER ) to $ 1,895m . Globally , new medicines represented 54 % of Total Revenue ( H1 2020 : 50 % ) 8,220 894 7,326 $ 0.42 $ 0.90 $ ( 0.01 ) Actual % Change 33 ( 23 ) 31 n / m 17 ( 27 ) ( 6 ) Q2 2021 CER % change 27 ( 23 ) 25 n / m n / m 12 ( 15 ) n / m Oncology growth of 19 % ( 15 % at CER ) to $ 6,360m and an increase in New CVRM of 21 % ( 16 % at CER ) to $ 2,731 m . Similarly , Respiratory & Immunology ( R & I ) increased by 11 % ( 6 % at CER ) to $ 2,970m , despite the adverse impact of mature , inhaled respiratory medicines on the performance in the half An increase in Emerging Markets of 26 % ( 21 % at CER ) to $ 5,459m with the performance benefitting from sales of the pandemic COVID - 19 vaccine of $ 455m . China growth of 21 % ( 11 % at CER ) to $ 3,209m . In the US , Total Revenue increased by 16 % to $ 4,834m and in Europe by 33 % ( 21 % at CER ) to $ 3,261m , also benefitting from sales of the pandemic COVID - 19 vaccine of $ 572m 1